TrialDiabetes, obesity & metabolism2020

Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB).

Toru Kitazawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.